CONFERENCE COVERAGE SERIES
Alzheimer's Association International Conference 2011
Paris, France
16 – 21 July 2011
Paris: Renamed ARIA, Vasogenic Edema Common to Anti-Amyloid Therapy
After disappointing trial results for Alzheimer’s disease drugs, all eyes are on the Phase 3 clinical trials of two monoclonal antibodies to Aβ...
Paris: Semagacestat Autopsy and Other News of Trial Tribulations
Last August, Eli Lilly and Company halted Phase 3 clinical trials of semagacestat after finding that patients on the medication fared worse than those on placebo...
Paris: More Trial News, Mixed at Best
With the buzz surrounding amyloid-targeting therapies, it is easy to lose sight of the fact that other treatments are being tested as well...
Paris: President and All, French Science Takes the Stage
President Sarkozy updated a packed hall on the Republic’s National Plan on Alzheimer's and related diseases that his administration implemented for the years 2008 to 2012...
Paris: Beyond Genomics, French Science Draws on Populations, Patients
One French research initiative <em>par excellence</em> is the European Alzheimer's Disease Initiative (EADI)—but many other efforts also stood out...
Paris: Studies Strengthen Link Between Brain Injury and Dementia
Some studies have shown that athletes who suffer repeated concussions develop a form of brain degeneration, different from AD, known as chronic traumatic encephalopathy...
Paris: Standardization a Hurdle for Spinal Fluid, Imaging Markers
In the fall of 2009, a large quality control (QC) program started comparing measurements of cerebrospinal fluid (CSF) biomarkers from labs across the world...